Opportunity
Quebec SEAO #45ce0919-e66c-41d8-9168-bf8346a6fab4
Procurement of Cyclomedica TECHNEGAS Plus Ventilation System for CHU de Québec-Université Laval
Posted
August 06, 2026
Respond By
August 17, 2026
Identifier
45ce0919-e66c-41d8-9168-bf8346a6fab4
NAICS
334510, 423450
This procurement opportunity is for the acquisition of a specialized medical ventilation system for CHU de Québec-Université Laval, under Santé Québec. - Government Buyer: - CHU de Québec-Université Laval (Santé Québec) - OEM Highlight: - Cyclomedica is specified as the Original Equipment Manufacturer (OEM) for the TECHNEGAS Plus ventilation system - Products/Services Requested: - TECHNEGAS Plus ventilation system - Includes all necessary accessories - Mobile cart with wheel brakes - Dedicated consumables (tubing and crucibles) for the equipment's lifespan - Technical and Regulatory Requirements: - Equipment must comply with Canadian standards (CAN/CSA C22.2 no. 60601 or 601) - Must have Health Canada approval - Must be resistant to specific cleaning protocols - Suitable for both adult and pediatric use - Must produce technetium-based aerosols with defined nanoparticle specifications - Must include alarms for argon flow issues - Procurement Process: - Sole-source justification based on unique clinical capabilities - Open to expressions of interest from qualified vendors able to meet all requirements - If a qualified alternative is identified, a public tender may be issued - No specific quantities or part numbers are provided in the solicitation
Description
The CHU de Québec-Université Laval intends to conclude a sole-source contract for the acquisition of the TECHNEGAS Plus system, which is the only system capable of meeting the clinical needs of the institution. The equipment must comply with relevant Canadian standards and certifications, be resistant to specific cleaning protocols, and produce technetium-based aerosols with defined nanoparticle sizes. The system must be delivered with a mobile cart and all necessary accessories, and be suitable for both adult and pediatric use. Interested companies should submit expressions of interest by August 16, 2026, with the contract expected to be finalized on August 21, 2026.